Small molecule kinase inhibitors (SMKIs) are a class of therapeutic drugs that target protein kinases in diseases such as cancer.
Kinases are among the most successful drug targets. To date, 72 small-molecule kinase inhibitors (SMKIs) have been approved by the US FDA, together with ~500 ...
Old Hard to Find TV Series on DVD
Small molecule kinase inhibitors (SMKIs) are one of the heightened concerns in the field of drug research and development. There are seventy-nine (up to ...
This School Cooperative Application is a new system that can provide ease of purchase, news, calendar and any information for teachers, parents and students ...
Fostamatinib is the precursor drug of active metabolite R406. It is a Syk inhibitor with an IC50 value of 41 nM. It strongly inhibits Syk ...
Evaluation of small molecule kinase inhibitors (SMKIs) as a multi-targeted therapeutic for the treatment of glioblastoma multiforme (GBM)?.
Small molecule kinase inhibitors (SMKIs) are being approved at a fast pace under expedited programs for anticancer treatment.
Small-molecule kinase inhibitors (SMKIs), 28 of which are approved by the US Food and Drug Administration (FDA), have been actively pursued as promising ...
New research directions, such as covalent and type III SMKIs, are emerging. Small-molecule kinase inhibitors (SMKIs), 28 of which are approved by the US ...